Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.44 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.44 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062625 | 0.85 | L3MBTL1 (0.63) | CYP19A1L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL28808278 | 0.85 | MAPT (0.44) | CYP19A1MAPTGABRA1GABRG2GABRB3 | |
| SCHEMBL29780834 | 0.85 | MAPT (0.44) | CYP19A1MAPTGABRA1GABRG2GABRB3 | |
| SCHEMBL31383537 | 0.82 | MAPT (0.59) | CYP19A1L3MBTL1MAPTLMNAMEN1 | |
| SCHEMBL4203356 | 0.82 | MAPT (0.59) | CYP19A1L3MBTL1MAPTLMNAMEN1 | |
| SCHEMBL15712823 | 0.81 | CCR2 (0.43) | CYP19A1MAPTGABRA1GABRG2GABRB3 | |
| SCHEMBL3052651 | 0.81 | CYP19A1 (0.59) | CYP19A1MAPTALDH1A1LMNACCR2 | |
| SCHEMBL16402263 | 0.80 | CYP19A1 (0.55) | CYP19A1L3MBTL1MAPTALDH1A1LMNA | |
| SCHEMBL17060361 | 0.79 | CCR2 (0.57) | ALDH1A1LMNACCR2 | |
| SCHEMBL17009677 | 0.79 | L3MBTL1 (0.50) | L3MBTL1MAPTALDH1A1LMNACCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728914-B | Dioxopiperazine derivative, preparation method thereof and application thereof in medicines | 深圳信立泰药业股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-114728914-A | Dioxopiperazine derivative, preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3138839-B1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3138839-B1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| CN-105829298-B | A kind of pyridone or pyrimidone derivatives, and its preparation method and application | 四川海思科制药有限公司 | 2019-02-01 | — | — | CN | disclosed |
| US-10174020-B2 | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-01-08 | — | — | US | disclosed |
| US-10174020-B2 | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-01-08 | — | — | US | disclosed |
| EP-3138839-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| EP-3138839-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170029423-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029423-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2017-02-02 | — | — | US | disclosed |
| US-20170029423-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2017-02-02 | — | — | US | disclosed |
| CN-105829298-A | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | 四川海思科制药有限公司 | 2016-08-03 | — | — | CN | disclosed |
| WO-2015120777-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 四川海思科制药有限公司 | 2015-08-20 | — | — | WO | disclosed |
| WO-2015120777-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 四川海思科制药有限公司 | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174020-B2 | Pyridone or pyrimidone derivative, preparation method therefor and application thereof | TYMP, DHFR, TYMS | CYP19A1 319/4885L3MBTL1 4397/4885MAPT 3830/4885 |
| US-20170029423-A1 | PYRIDONE OR PYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYMP, DHFR, TYMS | CYP19A1 319/4885L3MBTL1 4397/4885MAPT 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.